CAMBRIDGE, Mass. (AP) — Alnylam Pharmaceuticals Inc. said Tuesday it received $20 million from Takeda Pharmaceutical Co. Ltd. after transferring gene-silencing technology to the company.
Alnylam has been transferring technology, documents and materials connected to its RNAi program to Takeda, Japan's largest drugmaker for the past several years. RNAi technology is aimed at developing treatments that could shut down the protein at the root of a disease or condition.
Alnylam has already received $120 million in payments from Takeda. The Cambridge, Mass. company is still eligible for an additional $10 million.